Abstract:The upregulation of chemokine genes and the subsequent T-lymphocyte recruitment to the graft are early events in the development of acute cardiac transplant rejection or cardiac allograft vasculopathy. In the present study, a combined immunosuppressive regimen of C-X-C motif chemokine 9 (CXCL9) antibody (Ab), CXCL10 Ab and FTY720 was used in order to reduce the infiltration of memory T lymphocytes and prolong graft survival in a retransplantation murine model. BALB/c donor hearts were transplanted heterotopically into C57BL/6 mice at day 28 after skin transplantation. The mice were divided into four groups: i) Control (normal saline), ii) CXCL9 Ab and CXCL10 Ab [150 μg; once daily (qd); intraperitoneal (ip)], iii) FTY720 (0.2 mg/day; qd; ip) and iv) combined (2 mg/kg/day; qd; ip). Measurements of the median survival time of the cardiac grafts, histological examination, reverse transcription-quantitative polymerase chain reaction analysis, enzyme-linked immunosorbent assay and a mixed lymphocyte reaction were performed. The median graft survival time of the combined group was prolonged (9.3 days) compared with that of the control group (3.5 days) (P<0.001). Histological examination revealed that the combined treatment group graft rejection pathological score was 0.50, while the control group score was 3.62 (P<0.001). In addition, the gene expression level of interleukin (IL)-2 was significantly lower and the levels of IL-10 and transforming growth factor-β (TGF-β) were significantly higher in the combined group compared with those in the control group (P<0.001). Furthermore, the serum concentration levels of IL-2 and interferon-γ (IFN-γ) were significantly lower (P<0.001) and the concentration of IL-10 was significantly higher (P<0.05) in the combined group compared with those in the control group. In the mixed lymphocyte reaction, T-cell proliferation was found to be significantly lower in the combined treatment group than that in the control group (P<0.001). In conclusion, treatment with CXCL9 Ab and CXCL10 Ab or FTY720 reduced the graft infiltration of inflammatory cells, inhibited T-cell proliferation and prolonged graft survival. The combined treatment regimen of CXCL9 Ab, CXCL10 Ab and FTY720 was found to significantly reduce the infiltration of inflammatory cells in the graft and prolong graft survival.

A novel FK506-loading mesoporous silica nanoparticle homing to lymph nodes for transplant rejection treatment

Immunosuppressive effect of PLGA-FK506-NPs in treatment of acute cardiac rejection via topical subcutaneous injection

Helper T Cell (CD4 + ) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity

Immunosuppressive enzyme-responsive nanoparticles for enhanced accumulation in liver allograft to overcome acute rejection

Cell Communication‐Mediated Selective Drug Delivery for Epitope‐Specific Deletion of Alloreactive T Cells in Organ Transplant

Albumin Based Nanomedicine for Enhancing Tacrolimus Safety and Lymphatic Targeting Efficiency.

Lymph Node Targeted Drug Delivery for Effective Immunomodulation to Prolong the Long‐Term Survival After Heart Transplantation

Poly(Lactic-Co-Glycolic Acid) (PLGA) Nanoparticles Loaded with FK506 Inhibits Acute Heart Transplantation Rejection via Regulation of Monocyte Dendritic Cells Receptor

Preparation and evaluation of novel oral tacrolimus nanocochleates for organ transplantation to reduce individual differences and improve drug safety

Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy

Rapamycin Liposomes Targeted to Lymph Nodes Inhibit Dendritic Cell Maturation for the Treatment of Transplant Rejection

FK506-loaded PLGA nanoparticles improve long-term survival of a vascularized composite allograft in a murine model

Effect of Switch from Cyclosporine to FK506 on Renal Graft Outcome in Patients after Initial Acute Rejection

Development and effects of tacrolimus-loaded nanoparticles on the inhibition of corneal allograft rejection

Delivery of costimulatory blockade to lymph nodes promotes transplant acceptance in mice

In Vivo Kidney Allograft Endothelial Specific Scavengers for On‐Site Inflammation Reduction under Antibody‐Mediated Rejection

Combination of C-X-C motif chemokine 9 and C-X-C motif chemokine 10 antibodies with FTY720 prolongs the survival of cardiac retransplantation allografts in a mouse model

Chitosan nanoparticles encapsulated with BEZ235 prevent acute rejection in mouse heart transplantation

Targeting L‐Selectin Lymphocytes to Deliver Immunosuppressive Drug in Lymph Nodes for Durable Multiple Sclerosis Treatment

CLINICAL USE OF FK506 AS PRIMARY ANTI-REJECTION AGENT IN RENAL ALLOGRAFT RECIPEINTS

Nanoparticle-assisted Targeting Delivery Technologies for Preventing Organ Rejection